30.4 C
Vientiane
Monday, July 21, 2025
spot_img
Home Blog Page 152

Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)

SHANGHAI, May 30, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name: MAILISHENG, R&D code: 8MW0511) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing approval by National Medical Products Administration (NMPA). MAILISHENG is Mabwell’s first commercialized innovative drug, and is the first launched novel granulocyte colony-stimulating factor (G-CSF) developed with albumin long-acting fusion technology in China.

Albipagrastim alfa for Injection is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Albipagrastim alfa is a new generation of long-acting G-CSF (highly active modified cytokine) with intellectual property rights of Mabwell, which was developed with albumin fusion platform technology by fusing highly active recombinant G-CSF with human serum albumin (HSA). The modification increases the molecular weight, significantly inhibits the elimination pathway mediated by G-CSF receptor and prolongs the half-life of the drug in vivo, which improves the treatment adherence by reducing the frequency of administration in clinical practice. Compared to PEG-G-CSF, Albipagrastim alfa uses HSA as its natural carrier protein via a Pichia pastoris expression system. This approach offers a simpler production process and superior product homogeneity.

Mabwell previously presented results from a Phase III clinical study of 8MW0511 at the European Society for Medical Oncology (ESMO) annual meeting in 2023, and the full manuscript was published in May 2025 in Breast Cancer Research. 496 patients with breast cancer were enrolled and randomized into the study (8MW0511, n=331, control group, n=165). The result of study showed that 8MW0511 was clinically effective, non-inferior to the positive control. It is able to reduce the incidence of grade 4 neutropenia, significantly shorten the duration of grade 4 neutropenia and lower the incidence of Febrile Neutropenia (FN). The overall safety profile is similar to that of the positive control group, which indicates manageable safety profile and good tolerance in humans. The 8MW0511 group was superior to the control group in terms of the incidence of grade 4 neutropenia in cycle 1-4 of chemotherapy, the duration of grade 4 neutropenia, and the incidence of febrile neutropenia. Compared with the control group, the Absolute Risk Reduction (ARR) of grade 4 neutropenia was 3.1%, 7.0%, 4.2%, and 2.8%, while the Relative Risk Reduction (RRR) of grade 4 neutropenia was 15.6%, 68.4%, 58.3% in the 8MW0511 group during the cycle 1-4 of chemotherapy. RRR of FN was 42.0% [1]. The results of this study suggest that 8MW0511 has clinical advantages over the positive control drug, and safety advantages as a long-acting molecule using natural human proteins.

The phase III clinical trial of 8MW0511 also included a chemotherapy regimen of TAC (docetaxel, doxorubicin, and cyclophosphamide), which has a high risk of FN. Stratified analysis showed that comparing to the control group, the incidence of grade 4 neutropenia in the 8MW0511 group was slightly lower during the first cycle of chemotherapy, and significantly lower during cycle 2-4 of chemotherapy.

[1] Absolute Risk Reduction (ARR): the absolute difference in the percentage of patients who did not develop grade 4 neutropenia in the test group versus the control group. Relative Risk Reduction (RRR): the relative degree to which the risk of developing grade 4 neutropenia was reduced in the test group compared to the control group.

About Neutropenia

Neutropenia is a relatively common hematologic toxicity caused by chemotherapy with cytotoxic drugs, with studies showing that 65.5% of patients treated with chemotherapeutic agents such as paclitaxel, adriamycin, and cyclophosphamide experience a grade 3 or 4 decrease in their neutrophil counts. Febrile neutropenia (FN), as a clinical complication of chemotherapy, commonly results in prolonged hospitalization, increased use of broad-spectrum antibiotics and cost of therapy, reduction of chemotherapeutic agents or delayed chemotherapy, and ultimately affecting the efficacy of antitumor therapy. In more serious cases, it may lead to sepsis syndrome, infectious shock, and even death. Therefore, preventing or treating neutropenia and reducing the incidence of FN are fundamental to ensure adequate or dose-intensive chemotherapy.

Globally, more than 50% of new cancer cases require chemotherapy. The number of new tumor cases in 2025 is expected to be at 5.03 million (J Natl Cancer Cent. 2024,4(1)), and the number of patients who will require the first course of chemotherapy each year from 2018 to 2040 will increase from 9.8 million (corresponding to about 50 million chemotherapy cycles) to 15 million (corresponding to about 75 million chemotherapy cycles), i.e. an increase of 53%, according to an article published in the journal The Lancet Oncology. By 2040, more than 57.7% of cancer patients worldwide are expected to require chemotherapy. In addition, with the in-depth development of basic, translational and clinical oncology research, more individualized oncology treatment, and emergence of new antitumor therapeutics, drugs for the prevention or treatment of neutropenia hold great promise for application.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 16 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 4 products have been approved and commercialized, 1 product filed for pre-NDA meeting, 2 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for “Significant New Drugs Development”, 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell’s Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base in Shanghai and the ADC commercialized manufacturing base in Taizhou are under construction. Our mission is “Explore Life, Benefit Health” and our vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

Bruno Marc Redefines Summer Dressing with the Flex Oxford Collection

Versatile by Nature, Crafted for the Modern Man.

NEW YORK, May 30, 2025 /PRNewswire/ — This summer, Bruno Marc introduces the Flex Oxford Collection, a boundary-breaking lineup of hybrid dress shoes engineered for the modern man in motion. With three distinct series— CrossFlex, MaxFlex, KnitFlex —this collection redefines the classic Oxford by seamlessly blending tailored sophistication with athletic-level comfort, flexibility, and breathability.

Step into the future of footwear with Bruno Marc’s Flex Oxford Collection—engineered for modern movement and effortless all-day polish. Where timeless style meets unmatched comfort, every step delivers sophistication without the luxury price tag.
Step into the future of footwear with Bruno Marc’s Flex Oxford Collection—engineered for modern movement and effortless all-day polish. Where timeless style meets unmatched comfort, every step delivers sophistication without the luxury price tag.

As the lines between work and leisure continue to blur, footwear needs to do more than just look sharp—it must perform. The Flex Oxford Collection rises to this challenge, offering a refined silhouette that transitions effortlessly from boardroom meetings to city streets. Whether you’re navigating a busy day or heading out for an evening of style, these shoes combine the elegance of a dress shoe with the ease and energy of a sneaker, bridging fashion and function like never before.

CROSSFLEX SERIES – Timeless Style, Modern Comfort
Heritage-inspired and made for today’s demands, CrossFlex fuses traditional craftsmanship with upgraded features like scuff-resistant materials, breathable interiors, and flexible soles—built for all-day wear.

  • GentEdge Sharp Finish, Soft Core An ultra-smooth vamp and clean lines deliver elevated style, while the microfiber lining and latex-padded insole keep your feet cushioned from first coffee to late cocktails. Think tailored comfort in every step.
  • NeatPolish+ Old-School Oxford, New-Gen Energy Durable, scuff-resistant leather. A springy honeycomb foam insole. And under 10 oz, it weighs a quarter less than most dress styles. This is your new workhorse—built for polished routines and unpredictable days.
  • CrestHigh The Chukka That Can Weather Anything A modern ankle boot made for unpredictable schedules and weather. Water-resistant upper, breathable lining, and a removable sponge insole make this ankle boot a four-season favorite for both business and casual moments.

MAXFLEX SERIES – Performance Meets Polish
Athletic comfort, business-ready style. MaxFlex brings gym-inspired technology into elevated silhouettes for men who move fast and dress sharp.

  • SuiteCraft A Timeless Wingtip That Moves Like a Premium Sneaker Precision brogue details meet a responsive, rebound outsole with arch-lock support, giving you heritage style with sneaker agility. Designed for high-stakes days and high-mileage commutes.
  • SuiteCraft- Zero Break-In, All Business. Smooth leather, sweat-wicking perforations, and a shock-absorbing insole make this a dress shoe you won’t kick off at the end of the day. The lightweight design and foam-padded collar deliver effortless elegance on the go.
  • ActiveMetro Oxford look, athletic soul. Classic Oxford vibes meet an athleisure twist. This hybrid sneaker-Oxford sits on an ultra-bounce-back sole with a cupped insole that keeps your foot stable while commuting, traveling, or just chasing the next opportunity.

KNITFLEX SERIES – Lightweight & Breathable for Everyday Life
With sock-like fits, minimalist designs, and breathable knit uppers, KnitFlex is made for warm weather, quick getaways, and daily ease.

  • SmartCraft Coastal Cool Meets Office Casual These knit Oxfords strike the perfect balance—polished enough for the office, relaxed enough for the weekend. The breathable upper, cushioned memory foam insole, and easy slip-on collar offer all-day comfort whether you’re navigating morning meetings or grabbing lunch by the marina.
  • Breeze Light as Air, All Day Comfort At just 7.76 oz per shoe, Breeze delivers zero-gravity comfort with wingtip-inspired detailing for a dressed-up finish. The soft, flexible knit upper contours to your foot, providing a dynamic fit that moves with you. whether you’re traveling, enjoying warm weather, or tackling a busy day, Breeze delivers effortless support and style—step after step.
  • SmartCraft+ Sock-like fit meets elevated polish. SmartCraft+ combines the classic Oxford look with next-level comfort. The knit upper keeps feet breathable and flexible, while the cushioned EVA midsole ensures all-day support. Ideal for everything from meetings to dinner dates, SmartCraft+ offers a refined look and unbeatable comfort in one package.

Luxury Feel, Everyday Value
From light-as-air knits to engineered ergonomic soles, Bruno Marc’s Flex Collection turns traditional dress shoe expectations on their head. It’s a versatile wardrobe essential that meets the evolving demands of hybrid work, style fluidity, and modern movement. Bruno Marc’s Flex Collection doesn’t just look premium—it performs like it, too. Every pair is designed to withstand the demands of modern life without losing its shape or edge. Available now on Amazon, official website, TikTok, and in select retail stores.

About Bruno Marc
Bruno Marc is on a mission to redefine modern luxury, offering impeccably crafted footwear that embodies sophistication without the premium price. With an unwavering commitment to quality and refinement, Bruno Marc delivers shoes that blend timeless elegance with contemporary style, making high-end fashion accessible to every man. By prioritizing craftsmanship and attention to detail, Bruno Marc ensures that luxury is not just a statement but a standard, bringing a touch of sophistication to everyday life.

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001

  • Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications
  • Interim safety and pharmacokinetic data from BBT002-01 study anticipated in Q1 2026
  • The clearance of BBT001-01 study expands the clinical development territory of BBT001 beyond Australia into the United States
  • Bambusa has successfully advanced two differentiated bispecific programs—BBT001 and BBT002—into the clinic within 12 months of the company’s founding, underscoring its execution-first culture and translational rigor

BOSTON, May 30, 2025 /PRNewswire/ — Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced that it has completed the initial dosing in healthy volunteers (HV) in its clinical trial for BBT002, a novel, half-life extended bispecific antibody designed as a “platform in a molecule” with broad applications across respiratory, dermatology, and gastroenterology.

The Phase 1 clinical trial (BBT002-001; NCT06944925) is a randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study evaluating BBT002 in healthy volunteers and adults with COPD. The study will evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary efficacy of BBT002. Approximately 96 participants are expected to enroll across multiple sites. Interim safety and pharmacokinetic data are anticipated in the first quarter of 2026. Bambusa is also considering expanding into additional indications including asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis and food allergy, to fully realize the “platform-in-a-molecule” potential for BBT002.

“Advancing our second program into the clinic within just 12 months of founding Bambusa reflects the speed, precision, and high standards that define our development culture,” said Thang Ho, PhD, Senior Vice President of Development Sciences at Bambusa Therapeutics. “BBT002’s dual-target mechanism leverages two of the most classic and fundamental inflammatory pathways—enabling a rational, biology-driven approach to push the efficacy ceiling beyond what single-target therapies can achieve. We believe this strategy may offer additive or synergistic benefit, particularly for patients with complex, multi-organ inflammatory diseases. This milestone highlights our team’s ability to rapidly translate bold science into clinical-stage programs with broad impact.”

Separately, Bambusa also announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to proceed with the clinical development of BBT001, a novel multi-targeting, half-life extended bispecific antibody for the treatment of atopic dermatitis and other inflammatory skin diseases.  BBT001 is currently being studied in a randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study conducted in Australia, evaluating BBT001 in healthy volunteers and adults with moderate to severe atopic dermatitis. 

About Bambusa’s pipeline

BBT001 is a novel half-life extended bispecific antibody. Preclinical data with BBT001 demonstrate its best-in-disease potential, offering enhanced efficacy and improved dosing convenience compared to approved biologics in atopic dermatitis. It is currently being tested in a Phase I clinical study (BBT001-001; NCT06808477) 

BBT002 is a novel half-life extended bispecific antibody designed as a “platform in a molecule” with broad applications across respiratory, dermatology, and gastroenterology indications. Preclinical data with BBT002 demonstrate its best-in-disease potential, offering enhanced efficacy and improved dosing convenience compared to approved biologics across multiple inflammatory conditions. It is currently being tested in a Phase I clinical study (BBT002-001; NCT06944925).

The company’s additional pipeline candidates, BBT003 and BBT004, are being developed for inflammatory bowel disease and rheumatological conditions, each with best-in-disease potential.

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, Bambusa’s mission is to advance the field of immunology with cutting-edge solutions. For more information, visit www.bambusatx.com.

Bybit Earnival Unlocks 4 Weeks of Golden Rewards

DUBAI, UAE, May 30, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is excited to raise the stakes for Bybit Earn users in a four-week long rewards program, the Bybit Earnival. From now to June 22, eligible Bybit users may sign up for the event for a chance to earn up to 555% APR and Gold Tokens.

With paradigm shifts taking place in the global investment landscape, Bybit Earn offers a wide range of yield-bearing products catered to the diverse needs of traders. The offerings unlock access to beginner products with guaranteed returns such as flexible staking, advanced savings products at various risk levels, and tokenized real-world assets including XAUT, a digital token backed by physical solid gold.

For four weeks in a row, Bybit users may check into Bybit Earn for a rewarding experience packed with exclusive perks:

  • New User Exclusives: Users new to Bybit Earn can enjoy a boost for Fixed Savings products of up to 555% APR on USDT. The offer applies in the first two days after their initial deposit and staking of 100 to 300 USDT.
  • Extra APR Savings Products Every Week: Limited-time savings products with highly competitive APRs, starting at 500 USDT in net deposit, are refreshed daily at 6 AM UTC, with new offers launching every Monday at midnight.
  • Weekly Leaderboard Prize: Participants who acquire 3,000 USDT or more weekly in eligible Earn products can compete on the weekly leaderboard to win up to 1,000 USDT in Gold Tokens. Rankings update daily, and rewards are distributed within 7–14 days.

The event is open to verified retail customers with Savings service enabled on Bybit to ensure a fair and even level competition.

Bybit Earn is a popular tool for Bybit users to maximize the earning potential of their idle crypto assets on the trading platform. With a focus on consistent yield and regular promotions for higher APR, Bybit Earn is trusted by millions of users on Bybit, the one-stop solution for all their crypto needs.

Terms and conditions apply. For details and eligibility, users may visit Bybit Earnival.

#Bybit / #TheCryptoArk 

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

ISX Financial Reports Record Results in 2024 Annual Report – Revenue Up 81% Year-on-Year

NICOSIA, Cyprus, May 30, 2025 /PRNewswire/ — ISX Financial EU Plc (“ISXPlc”), an innovative provider of regulated transactional banking services and real-time payment technology in the UK and Europe, today released the financial highlights of its 2024 Audited Annual Report, marking another record-breaking year of growth, profitability, and innovation.

2024 Financial Highlights

Robust Growth
ISXPlc reported revenue of €58.7 million for the financial year 2024, reflecting an 81% year-on-year increase. This growth was driven by surging transaction volumes, strong client acquisition, and strategic investments. ISXPlc’s software subsidiary, Probanx, contributed more than €2.5 million to the Group’s total revenue.

Financial Strength
ISXPlc achieved an industry-leading EBITDA margin of 61%, representing a 30% improvement compared to the previous year. This margin expansion underscores the scalability of the company’s model and the strength of its diversified client base.

Innovation Focus
In 2024, ISXPlc invested €2.8 million in Research & Development through its Probanx subsidiaries, accelerating product delivery and continuous platform enhancements. These investments support the company’s ongoing commitment to pioneering secure, intelligent payments and regulatory technology solutions.

Trusted Partner
Client balances held under custody rose by 56% to €189 million, reflecting increased trust from ISXPlc’s growing network of business customers. As a prudentially regulated institution, safeguarding client funds remains a cornerstone of ISXPlc’s reputation and service delivery.

Product and Partnership Development
In the fourth quarter, ISXPlc launched its SEPA Direct Debit with Notification service and completed a strategic investment in an AI-focused business. The Group’s 2025 product roadmap includes several innovations and enhancements developed and delivered by its Probanx subsidiaries.

Community Engagement
With a substantial portion of its team based in Cyprus, ISXPlc reaffirmed its commitment to community engagement. In 2024, the company continued its long-standing partnership with Ronald McDonald House through both financial support and staff volunteering. ISXPlc also hosted a successful national blood donation drive and expanded its “Dream Big” Initiative, promoting youth participation in sport. Additionally, ISXPlc was proud to sponsor Olympic fencer Alexander Tofalides and the Cyprus Rugby Federation.

Outlook for 2025
Despite macroeconomic turbulence in early 2025, ISXPlc is targeting full-year revenues of €60–65 million while maintaining profitability margins in the 30–40% range. The company remains confident in its ability to execute on its strategy, driven by innovation, operational excellence, and disciplined growth.

View the 2024 Annual Report here: https://www.isx.financial/blog/annual2024

About ISX Financial EU Plc
ISX Financial EU Plc is a leading UK and EU-based electronic money institution and transactional banking provider, offering secure, real-time payments via bank and card rails. Through its wholly-owned subsidiary Probanx, ISXPlc delivers cutting-edge Software-as-a-Service (SaaS) solutions to banks and financial institutions across the globe, including interconnecting banks with central banks.

For more information, visit www.isx.financial

Media enquiries: +35722015740, media@isxfinancial.com 

BingX Strengthens Its Executive Team by Appointing Daniel Lai as Chief Business Officer

PANAMA CITY, May 30, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, is pleased to announce the appointment of Daniel Lai as its Chief Business Officer. In this strategic leadership role, Daniel will steer BingX’s key business initiatives, with a focus on market expansion, risk management, compliance frameworks, and security partnerships. His appointment reflects BingX’s continued commitment to sustainable growth, global reach, and building a secure, user-first trading environment.

Daniel brings a wealth of experience from leadership roles at prominent crypto platforms and fintech companies, offering deep expertise in navigating complex markets and fostering cross-functional collaboration. In addition to his professional accomplishments, Daniel’s diverse academic background and cross-disciplinary insights will be instrumental in strengthening BingX’s global security alliances and developing adaptable compliance structures suited to the rapidly evolving digital asset landscape.

Daniel Lai shared his thoughts on the appointment: “I’ve always believed that trust and security are the cornerstones of crypto space, and I’m excited to bring my experience to BingX, where these values are central to the company’s mission. Joining a forward-thinking organization like BingX, especially during this pivotal phase of BingX AI Evolution, is incredibly inspiring. At BingX, every decision is driven by the goal of providing long-term value to our users, creating a space where they feel confident and supported. The company’s user-first vision truly resonates with me, and I’m honored to be part of this journey to make a lasting impact on the crypto world.”

In welcoming Daniel to the team, BingX reaffirms its commitment to driving innovation and ensuring the highest standards of security and compliance in the cryptocurrency space. The company looks forward to seeing the positive impact of Daniel’s leadership as it continues to expand and enhance its offerings for users worldwide. With this strategic addition, BingX is poised to further solidify its position as a leader in the market, embodying trust, innovation, and excellence.

About BingX 

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information please visit: https://bingx.com/

Dynatrace Names DXC Global Partner of the Year

ASHBURN, Va., May 30, 2025 /PRNewswire/ — DXC Technology, a leading Fortune 500 global technology services provider, today announced it has been named Global Partner of the Year at the Dynatrace Amplify Partner Sales Kickoff. The award recognizes DXC’s 15-year strategic collaboration with Dynatrace—marked by deep technical expertise, strategic investment, and transformative results for enterprise customers worldwide. 

Dynatrace Names DXC Global Partner of the Year
Dynatrace Names DXC Global Partner of the Year

The Global Partner of the Year Award honors organizations that demonstrate exceptional innovation and drive market adoption for Dynatrace solutions. DXC earned this distinction for its ability to leverage innovative solutions from Dynatrace to foster growth and success, consistently exceeding expectations and addressing the evolving needs of enterprises.  DXC was also recognized for spearheading the establishment of a Dynatrace strategic business unit, with more than 280 certified engineers and over 1,500 trained professionals worldwide.

“This recognition underscores the power of our partnership and the trust our customers place in our joint solutions,” said Howard Boville, President, DXC Consulting & Engineering Services Powered by AI. “In just the past 15 months, we’ve helped more than 200 organizations, including some of the most complex enterprises in the world—adopt Dynatrace. With the industry’s largest team of Dynatrace-certified engineers, a dedicated business unit, and automation that facilitates onboarding in minutes, we’re enabling clients to accelerate transformation, resolve issues faster, and realize the full value of AI-powered observability.”

It’s my honor to congratulate DXC Technology on being named our 2025 Global Partner of the Year. This well-deserved award reflects DXC’s remarkable commitment to innovating and driving market growth, and we couldn’t be prouder to recognize their achievements. Our combined potential to deliver true business outcomes is only increasing, and we look forward to building on this success and delivering even greater impact in the year to come ,”  said Jay Snyder, SVP, Global Partners and Alliances, Dynatrace. 

DXC brings unparalleled scale and expertise to the Dynatrace ecosystem, with one of the largest investments in Dynatrace talent across the IT industry. DXC’s dedicated Global Dynatrace Strategic Business Group reflects its commitment to delivering next-generation observability solutions for our customers. DXC is also the only IT services provider with a Center of Excellence focused on Logs Management on Grail, which highlights our leadership in applying AI to enterprise-scale applications.

To learn more about how DXC is partnering with Dynatrace to drive innovation and deliver powerful outcomes on a global scale, visit here.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.

Dynatrace and Grail are trademarks of the Dynatrace, Inc. group of companies.

 

NYSE Content Advisory: Pre-Market update + April inflation data released

NEW YORK, May 30, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on May 30th

  • Stocks are little changed Friday as traders continue to parse through headlines. The Court of International Trade halted the bulk of President Trump’s tariffs Wednesday. It then granted a stay on Thursday, permitting them until next week
  • Treasury Secretary Scott Bessent told Fox News that U.S.-China trade talks are “a bit stalled.” Bessent led the U.S. and China to a temporary agreement in Switzerland in early May after a rapid escalation in tensions in April.
  • Q1 GDP data yesterday showed the U.S. economy contracted two-tenths of a percent from January through March. The Fed’s preferred inflation gauge today is expected to show pace of price gains increase 2.2% in April from a year ago.

Opening Bell
Darden Restaurants (NYSE: DRI) celebrates the 30th anniversary of its listing on the NYSE

Closing Bell
Tech: NYC celebrates New York’s thriving tech industry through the pre-launch of Obviously NYC

Click here to download the NYSE TV App